Aernoud Fiolet

253 Short-term effect of low-dose colchicine on biomarkers 19. Stone NJ, Robinson JG, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Part B):2889–934. 20. Lehmann EL. Nonparametrics: Statistical Methods Based on Ranks, Revised. Springer-Verlag; NewYork; 1998. pages 76–81. 21. Deftereos S, Giannopoulos G, Panagopoulou V, Bouras G, Raisakis K, Kossyvakis C, et al. Anti- inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study. JACC Hear Fail. 2014;2(2):131–7. 22. Demidowich AP, Levine JA, Onyekaba GI, Khan SM, Chen KY, Brady SM, et al. Effects of colchicine in adults with metabolic syndrome: A pilot randomized controlled trial. Diabetes, Obes Metab. 2019. April 2;21(7):1642–51. 23. Raju NC, Yi Q, Nidorf M, Fagel ND, Hiralal R, Eikelboom JW. Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial. J Thromb Thrombolysis. 2012;33(1):88–94. 24. Hennessy T, Soh L, Bowman M, Kurup R, Schultz C, Patel S, et al. The low dose colchicine after myocardial infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. Am Heart J. 2019. June 14;215:62–9. 25. Ikonomidis I, Athanassopoulos G, Lekakis J, Venetsanou K, Marinou M, Stamatelopoulos K, et al. Myocardial Ischemia Induces Interleukin-6 and Tissue Factor Production in Patients With Coronary Artery Disease. Circulation. 2005. November 22;112(21):3272–9. 26. Orn S, Manhenke C, Ueland T, Damas JK, Mollnes TE, Edvardsen T, et al. C-reactive protein, infarct size,microvascular obstruction, and left-ventricular remodelling following acutemyocardial infarction. Eur Heart J. 2009. May 2;30(10):1180–6. 27. Vaidya K, Arnott C, Martínez GJ, Ng B, McCormack S, Sullivan DR, et al. Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome: A CT Coronary Angiography Study. JACC Cardiovasc Imaging. 2018;11(2):305–16. 28. Libby P. Interleukin-1 Beta as a Target for Atherosclerosis Therapy. J Am Coll Cardiol. 2017. October 31;70(18):2278–89. 29. Consortium IL-1. Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol. 2015;3(4):243–53. 30. Consortium IL-6 The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379(9822):1214–24. 31. Martinez GJ, Robertson S, Barraclough J, Xia Q, Mallat Z, Bursill C, et al. Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome. J Am Heart Assoc. 2015. August 24;4(8):e002128 32. Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018. October 7;39(38):3499–507. 33. Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum. 1998;28(1):48–59. 34. Phelps P. Polymorphonuclear leukocyte motility in vitro. IV. colchicine inhibition of chemotactic activity formation after phagocytosis of urate crystals. Arthritis Rheum. 1970;13(1):1–9. 35. Levy M, Eliakim M. Long-term colchicine prophylaxis in familial Mediterranean fever. Br Med J. 1977;2(6090):808